Archived Medical News Stories

<< Back to Main Archives Index

RSSArchived Drug Trial News Stories - October 2011

Date Title Comments Rating
2011-10-31 Aspirin may reduce risk of bowel cancer by half: Study 0 None
2011-10-31 Initiation of two IPI-145 Phase 1 clinical trials triggers $4M milestone payment to Intellikine 0 None
2011-10-31 Vegenics receives IND approval from FDA for VGX-100 Phase I study in late stage cancers 0 None
2011-10-31 Infinity commences two IPI-145 Phase 1 clinical trials for hematologic malignancies 0 None
2011-10-31 Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tumors 0 None
2011-10-31 YM BioSciences announces results of nimotuzumab Phase II study on DIPG 0 None
2011-10-31 Fierce Vaccines highlights Inovio's VGX-3100 as one of 10 Promising Therapeutic Vaccines 0 None
2011-10-31 HAL Allergy initiates PURETHAL Mites PHASE II study 0 None
2011-10-29 Ovarian cancer patients with many folate receptors benefit from new therapy 0 None
2011-10-29 Glitazone treatment does not cause side effects in patients with metastatic thyroid cancer 0 None
2011-10-29 Not too early to consider funding for, distribution of malaria vaccine 0 None
2011-10-29 Some experts question early release of RTS,S malaria vaccine trial data 0 None
2011-10-29 BZL and ATLAB Pharma partner to develop 177Lu-J591 for metastatic prostate cancer treatment 0 None
2011-10-28 Reasons for caution about experimental malaria vaccine 0 None
2011-10-28 Sulodexide drug fails to benefit diabetes patients with kidney disease 0 None
2011-10-28 Lenvatinib may achieve partial response in thyroid, endometrial, and renal cancers 0 None
2011-10-28 Diabetic patients with mild kidney disease may benefit from vitamin B6 derivative 0 None
2011-10-28 Regeneron announces positive results from sarilumab Phase 2b trial on RA 0 None
2011-10-27 Bayer's regorafenib Phase 3 trial on metastatic colorectal cancer meets primary endpoint 0 None
2011-10-27 Gardasil vaccine safe and effective against anal cancer 0 None
2011-10-24 Biogen’s Multiple Sclerosis pill succeeds at a late phase clinical trial 0 2
2011-10-24 external Trigeminal Nerve Stimulation pediatric clinical trial for ADHD receives NeuroSigma funding 0 None
2011-10-24 Sustained 'vigilance and money' necessary to fight malaria 0 None
2011-10-24 Tenofovir gel confirmed to be effective against herpes in lab experiment, study shows 0 None
2011-10-24 FDA approves intraspinal injections in spinal cord stem cell ALS trial 0 5
2011-10-24 Lundbeck's ONFI receives FDA approval for treating seizures associated with Lennox-Gastaut syndrome 0 None
2011-10-24 European CHMP adopts positive opinion for Pharmaxis Bronchitol Marketing Authorisation 0 None
2011-10-24 Zeaxanthin reduces risk for AMD 0 None
2011-10-24 Vertex initiates INCIVEK combination Phase 3b study for hepatitis C 0 None
2011-10-24 Synergy commences plecanatide Phase II/III trial in chronic idiopathic constipation 0 None
2011-10-24 Top-line results from Exelixis' cabozantinib phase 3 trial on medullary thyroid cancer 0 None
2011-10-24 Mesoblast cleared to begin first phase 2 clinical trial for wet AMD 0 None
2011-10-24 Mirna, Silence enter agreement to assess delivery systems for novel microRNAs 0 None
2011-10-22 Pivotal pediatric clinical study comparing Q/LAIV to FluMist meets primary endpoint 0 None
2011-10-22 Abbott, Biogen Idec announce additional results from daclizumab HYP Phase 2b trial for RRMS 0 None
2011-10-22 Sanofi announces new results from alemtuzumab-Rebif comparative CARE-MS I trial 0 None
2011-10-22 Ferring reports on FDA approval of labeling supplement for EUFLEXXA to treat knee osteoarthritis 0 None
2011-10-22 Pfizer's Prevnar 13: Additional data from adult clinical studies presented at 49th IDSA 0 None
2011-10-22 Janssen announces FDA label update approval for PREZISTA HIV tablets 0 None
2011-10-22 Additional data from Sanofi's quadrivalent inactivated influenza vaccine study 0 None
2011-10-22 Merz presents XEOMIN clinical data on dystonia at IDS 2011 0 5
2011-10-22 Positive top line results from Shire's LDX phase III study on ADHD 0 None
2011-10-22 NIH stops triple-drug therapy clinical trial for idiopathic pulmonary fibrosis 0 None
2011-10-22 Much work remains to be done in fight against malaria 0 None
2011-10-22 Romark announces results from NT-300 Phase 2B-3 trial on influenza 0 None
2011-10-22 Xencor commences XmAb5871 Phase 1 trial in autoimmune diseases 0 None
2011-10-22 Boehringer Ingelheim announces new data from hepatitis C virus portfolio 0 None
2011-10-21 Geron announces data from ongoing GRNOPC1 Phase 1 trial on spinal cord injury 0 None
2011-10-21 Genentech announces 96-week results from ocrelizumab Phase II study on RRMS 0 None
2011-10-21 OncoGenex commences enrollment in OGX-427 Phase II trial for bladder cancer 0 None
2011-10-20 Starting HIV therapy within two weeks of TB treatment increases survival by 33% 0 None
2011-10-20 TGen collaborates with Samuel Oschin Comprehensive Cancer Institute for clinical trials 0 None
2011-10-20 Rituximab may alleviate chronic fatigue syndrome through B-lymphocyte depletion 0 5
2011-10-20 EMA, FDA endorse use of biomarkers in Alzheimer's drug trials 0 None
2011-10-20 Despite progress in malaria vaccine development, funding remains potential stumbling block 0 None
2011-10-20 Experimental vaccine halves risk of malaria in African children, results of large clinical trial suggest 0 None
2011-10-19 Data from Concert Pharmaceuticals' CTP-499 study to be presented at ASN Kidney Week 2011 0 None
2011-10-19 Oral laquinimod shows promise against multiple sclerosis 0 5
2011-10-19 Topical corticosteroids show promise against bacterial corneal ulcers 0 None
2011-10-19 RTS,S vaccine reduces risk of severe malaria in African children 0 None
2011-10-18 First results from phase 3 malaria vaccine candidate trial 0 None
2011-10-18 FDA approves Oxford BioMedica's UshStat IND to treat Usher syndrome type 1B 0 5
2011-10-18 Takeda commences TAK-875 Phase 3 clinical trial program for type 2 diabetes 0 None
2011-10-18 Natroba effective against head lice and nits 0 None
2011-10-18 Positive results from Roche's Phase 3 HannaH trial for HER2-positive early breast cancer 0 None
2011-10-18 Dendreon initiates enrollment in DN24-02 Phase 2 trial for HER2 positive cancer 0 None
2011-10-18 ChemoCentryx commences CCX168 Phase II trial in ANCA-associated vasculitis 0 None
2011-10-15 ABI provides clinical update on company activities 0 None
2011-10-15 Janssen, BeiGene enter in-licensing agreement for two clinical-stage oncology compounds 0 None
2011-10-14 Four companies receive NIAID contracts to develop broad-spectrum therapeutics 0 None
2011-10-14 NIH-funded study to evaluate rescue medications for victims of toxic gases 0 None
2011-10-14 USAID award supports study of SILCS diaphragm plus tenofovir gel on HIV, HSV 0 None
2011-10-14 New dual drug combinations in development for various cancers 0 None
2011-10-14 Merck announces results from ISENTRESS Phase III combination study on HIV-1 0 None
2011-10-14 Micromet receives FDA feedback on blinatumomab registration for R/R ALL 0 None
2011-10-14 Positive data from Anadys' setrobuvir Phase IIb combination study on genotype 1 HCV 0 None
2011-10-14 JCO publishes Keryx's KRX-0401 Phase 1 / 2 combination study on advanced MM 0 None
2011-10-14 Baxter commences BAX 111 Phase III trial in von Willebrand disease 0 None
2011-10-14 InnaVirVax announces Phase I/IIa clinical trial authorization for its VAC-3S HIV vaccine 0 None
2011-10-13 Top-line results from POZEN's PA32540 Phase 3 trial on aspirin-associated gastric ulcers 0 None
2011-10-13 Hydromorphone can be as effective as diacetylmorphine in treating heroin addiction 0 None
2011-10-13 EMA recommends 4SC's resminostat for orphan medicinal product designation to treat HL 0 None
2011-10-12 Intellikine commences INK1117 Phase I dose escalation study in cancer 0 None
2011-10-12 Vitamin E supplements linked with increased risk of prostate cancer 0 None
2011-10-12 Daily vitamin E supplementation may increase risk of prostate cancer 0 None
2011-10-12 FDA grants Advaxis pre-IND meeting for ADXS-HER2 cancer immunotherapy 0 None
2011-10-12 AFFiRiS receives MJFF grant for clinical study of AFFITOPE PD01 0 None
2011-10-12 Shield commences two ST10 Phase 3 studies in iron deficiency anaemia 0 None
2011-10-12 NIH awards United Therapeutics $45 million contract to develop potential oral treatment for viruses 0 None
2011-10-12 Isis designates ISIS-AATRx candidate in collaboration with GSK 0 None
2011-10-12 Merrimack begins MM-121 Phase 2 combination trial in HER2-negative breast cancer 0 None
2011-10-12 Furiex announces publications and presentations about antibacterial drug JNJ-Q2 0 None
2011-10-12 UCSF, Anacor to discover and optimize novel oxaboroles as antimalarial drugs 0 None
2011-10-12 COPAXONE reduces loss of brain volume in patients with RRMS 0 None
2011-10-12 Boston Therapeutics initiates PAZ320 clinical trial in Type 2 Diabetes 0 None
2011-10-11 DMC completes review of BioSante's LibiGel Phase III cardiovascular and breast cancer study 0 None
2011-10-11 Omeros initiates OMS302 Phase 3 trial in intra-ocular lens replacement surgery 0 None
2011-10-11 DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer 0 None
2011-10-11 Aduro initiates CRS-207 and GVAX Pancreas Cancer Vaccine Phase 2 clinical trial 0 None
2011-10-11 ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM 0 4
2011-10-11 Roche's gantenerumab removes amyloid plaques from the brain of patients with AD 0 None
2011-10-11 Takeda, Affymax announce data from multiple studies of peginesatide on anemia 0 None
2011-10-11 Positive results from Biotron's BIT225 Phase 2a trial on HCV 0 None
2011-10-10 Coridon demonstrates 100% protection using DNA HSV-2 vaccine 4 5
2011-10-10 Targacept commences AZD3480 Phase 2b study in Alzheimer’s disease 0 None
2011-10-10 Unither Virology receives NIAID contract for glycobiology antiviral platform 0 None
2011-10-10 Pharmasset adds two treatment arms to PSI-7977 ELECTRON trial on HCV 0 None
2011-10-07 Teriflunomide drug reduces relapse rate of people with MS 0 None
2011-10-07 JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer 0 None
2011-10-04 Karo Bio initiates patient recruitment in eprotirome phase III trial for HeFH 0 4
2011-10-04 Clinical study: Higher radiation dose does not improve overall survival for NSCLC 0 None
2011-10-04 DNA primer vaccine enhances immune response to H5N1 avian influenza vaccine 0 None
2011-10-04 Orexigen presents data from Contrave trial at 29th Annual Scientific Meeting of The Obesity Society 0 None
2011-10-04 Santaris Pharma to report new clinical data from miravirsen Phase 2a study on HCV 0 None
2011-10-04 AMRI announces final results from ALB-127158(a) Phase I clinical studies on obesity 0 None
2011-10-03 Sangamo's SB-509 fails to meet key endpoints in Phase 2b study for diabetic neuropathy 0 None
2011-10-03 EntreMed announces data from ENMD-2076 Phase 2 study in platinum-resistant ovarian cancer 0 None
2011-10-03 Dosing commences in Auxilium's XIAFLEX phase IIIb trial for Dupuytren's contracture 0 None
2011-10-03 GeoVax completes enrollment for HIV/AIDS vaccine Phase 2a clinical trial 0 None
2011-10-03 Alkermes initiates ALKS 37 phase 2b study in opioid-induced constipation 0 None
2011-10-01 The Polyclinic participates in major international HDL clinical research study 0 None
2011-10-01 Planned clinical trial of Adeona's zinc-based therapy for ALS patients to be featured at ALS Summit 0 None
2011-10-01 Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011 0 None
2011-10-01 Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA 0 None
2011-10-01 New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011 0 None
2011-10-01 Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting 0 None
2011-10-01 Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer 0 None
2011-10-01 Baxter seeks European marketing authorization for HyQ to treat PI 0 None

Total

128 posts
4 comments
10 raters